FT-836

N/A

Report date: 2025/10/16 20:00:08

Base Information

Drug NameFT-836
Drug Alias NameFT-836FT836
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsAnti-MICAAnti-MICB
TargetsMHC class I polypeptide-related sequence AMHC class I polypeptide-related sequence B
Therapy Area/IndicationsEndometrial NeoplasmsCarcinoma, Non-Small-Cell LungOvarian Neoplasms +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesFate Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesFate Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsEndometrial NeoplasmsCarcinoma, Non-Small-Cell LungOvarian Neoplasms +[6] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A